—  SHORT COURSE  —

USES AND LIMITATIONS OF ANCILLARY TECHNIQUES
APPLIED TO CYTOPATHOLOGY

Jeffrey S. Ross, M.D.




REFERENCES
  1. Listrom MB, Fenoglio-Preiser CM: Immunochemistry in cytology. In Koss LG, Diagnostic Cytology and Its Histopathologic Basis. Philadelphia: JB Lippincott and Co, 1992: pp 1532-1566, .

  2. Osborn M, Domagala W. Immunocytochemistry. In Bibbo M, Comprehensive Cytopathology. Philadelphia: WB Saunders Co, 1992: pp 1011-1051.

  3. Flens MF, van der Valk P, Tadema T, et al. The contribution of Immunocytochemistry in diagnostic cytology. Cancer 1990; 65:2704-2711.

  4. Osamura RY. Applications of immunocytochemistry to diagnostic cytopathology. Diagn Cytopathol 1989; 5:55-63.

  5. Myers JD. Development and application of immunocytochemical staining techniques: A review. Diagn Cytopathol 1989; 5:318-330.

  6. Nadji M. The potential value of immunoperoxidase techniques in diagnostic cytology. Acta Cytol 1980: 24:442-447.

  7. Shield PW, Perkins G, Wright RG. Immunocytochemical staining of cytologic specimens. How helpful is it? Am J Clin Pathol 1996; 105:107-162.

  8. Lai C-R, Pan C-C, Tsay S-H. Contribution of immunocytochemistry in routine diagnostic cytology. Diagn Cytopathol 1995; 14:221-225.

  9. Taylor CR. The total test approach to standardization of immunohistochemistry. Arch Pathol Lab Med 2000; 124:945-951.

  10. Domagala W, Markiewski M, Tuziak T, Kram A, Weber K, Osborn M. Immunocytochemistry on fine-needle aspirates in paraffin miniblocks. Acta Cytol1990; 34:291-296.

  11. Taylor CR. Concerted efforts in the standardization of immunohistochemistry. Human Pathol 1994; 25:2-11.

  12. Taylor CR. The current role of immunohistochemistry in diagnostic pathology. CR Mosby Yearbook in Pathology. 1994; pp 59-105.

  13. Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. JNCI 1996; 88:1054-1059.

  14. Williams JH, Mepham BL, Wright DH. Tissue preparation for immunohistochemistry. J Clin Pathol 1997; 50:422-428

  15. O'Leary TJ. Standardization in immunohistochemistry. Appl Immunohist Molec Morphol 2001;9:3-8.

  16. Leong A S-Y. Immunostaining of cytologic specimens. Am J Clin Pathol 1996; 105:139-140.

  17. Imlay SP, Raab SS. Pleural fluid cytology: Immunocytochemistry usage patterns and significance of nondefinitive diagnoses. Diagn Cytopathol 2000; 22:281-285.

  18. Mitteldorf CATS, Alves VAF, Kanemura CT et al. Immunocytochemistry applied to aspiration biopsy cytology. Acta Cytol 1999; 43:218-226.

  19. Raab SS. The cost-effeictiveness of immunohistochemistry. Arch Pathol Lab Med 2000; 124:1185-1191.

  20. Leong ASY, Suthipintawong C, Vinyuvat S. Immunostaining of cytologic preparations: a reviewof technical problems. Appl Immunohist MolecMorph 1999; 7:214-220.

  21. El-habashi A, El-morsi B, Freeman SM, El-didi M, Marrogi AJ. Tumor oncogenic expression in malignant effusion as a possible method to enhance cytologic diagnostic sensitivity. Am J Clin Pathol 1995; 103:206-214.

  22. Werner M, Chott A, Fabiano A, Battifora H. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 2000; 24:1016-1019.

  23. Miller RT, Swanson PE, Wick MR. Fixation and epitope retrieval in diagnostic immunohistochemistry: a concise review with practical considerations. Appl Immunohist Molec Morph 2000; 8:228-235.

  24. Frost AR, Sparks D, Grizzle WE. Methods of antigen recovery vary in their usefulness in unmasking specific antigens in immunohistochemistry. Appl Immunohist Molec Morph 2000; 8:226-235.

  25. Kurtycz DFI, Logrono R, Leopando M et al. Immunocytochemistry controls using cell culture. Diagn Cytopathol 1997; 17:74-79.

  26. Travis WD, Wold LE. Immunoperoxidase staining, fine-needle aspiration specimens previously stained by the Papanicolaou technique. Acta Cytol 1987; 31:517-520.

  27. Kung ITM, Chan S-K, Lo ESF. Application of the immunoperoxidase technique to cell block preparation from fine-needle aspirates. Acta Cytol 1990; 34:297-303

  28. Duggan MA, Masters CB, Alexander F. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic carcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin. Acta Cytol 1987; 31:807-814.

  29. Kahn J, Hanna W, Yeger H, Baumal R. Immunohistochemical localization of prekeratin filaments in benign and malignant cells in effusions: Comparison with intermediate filament distribution by electron microscopy. Am J Pathol 1982; 109:206-214.

  30. Ramaekers F, Haag D, Jap T, Vooijs GP. Immunochemical demonstration of keratin and vimentin in cytologic aspirates. Acta Cytol 1984; 28:385-392.

  31. Holmes GF, Eisele DW, Rosenthal D et al. PSA immunoreactivity in a parotid oncocytoma. Diagn Cytopathol 1998; 19:221-225.

  32. Zarghami N, D'Costa M, Tsuyuki D et al. Expression of prostate specific antigen gene in lung tissue. Clin Cancer Res 1997; 3:1201-1206.

  33. Liu H, Moy P, Kim S et al. Monoclonal antibodies to the extracellular domain of the prostate specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997; 57:3629-3634.

  34. Singh HK, Silverman JF, Berns L, Haddad MG, Park HK. Significance of epithelial membrane antigen in the workup of problematic serous effusions. Diagn Cytopathol 1995; 13:3-7.

  35. Queiroz C, Barral-Netto M, Bacchi CE. Characterizing subpopulations of neoplastic cells in serous effusions. The role of immunocytochemistry. Acta Cytol 2001;45:18-22.

  36. Masood H, Lu L, Assaf-Munasifi M, McCaulley K. Application of immunostaining for muscle specific actin in detection of myoepithelial cells in breast fine-needleaspirates. Diagn Cytopathol 1995; 13:71-74.

  37. Robins DB, Katz RL, Swan F Jr., Atkinson EN, Ordonez NG, Yo H. Immunotyping of lymphoma by fine-needle aspiration: A comparative study of cytospin preparations and flow cytometry. Am J Clin Pathol 1994; 101:569-576.

  38. Abdulla M, Bui HX, del Rosario AD, Wolf BC, Ross JS. Renal angiomyolipoma. DNA content and immunohistochemical study of classic and multicentric variants. Arch Pathol Lab Med 1994; 118:735-39.

  39. Bedrossian CWM. Diagnostic problems in serous effusions. Diagn Cytopathol 1998; 19:131-137.

  40. Delahaye M, van der Ham F, van der Kwast TH. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. Diagn Cytopathol 1997; 18:115-120.

  41. Zimmerman RL, Fogt F, Goonewardene S. Diagnostic utility of BCA-225 in detecting adenocarcinoma in serous effusions. Anal Quant Cytol Histol 2000; 22; 353-357.

  42. Donna A, Per-Giacomo B, Chiodera P et al. Newly marketed tissue markers for malignant mesothelioma. Human Pathol 1997; 28:931-9337.

  43. Ordonez N. The immunohistochemical diagnosis of epthelial mesothelioma. 1999; 30:313-323.

  44. Ordonez N. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoa. Am J ClinPathol 1999; 112:75-89.

  45. Risberg B, Davidson B, Dong HP, Nesland JM, Berner A. Flow cytometric immunophenotyping of serous effusuions and peritoneal washings: comparison with immunocytochemistry and morphological findings. J Clin Pathol 2000; 53:513-517.

  46. Schofield K, D'Aquila T, Rimm DL. E-cadherin expression is a sensitive and specific method for detection of carcinoma cells in fluid specimens. Diagn Cytopathol 2000; 22:263-267.

  47. Dabbs DJ, Abendroth CS, Grenko RT et al. Immunocytochemistry on the thin-prepR processor. Diagn Cytopathol 1997; 17:388-392.

  48. Leung SW, Bedard YC. Immunocytochemical staining of thin-prep processed smears. Modern Pathol 1996; 9:302-306.

  49. Simsir A, Fetsch P, Stetler-Stevenson M et al. Immunophenotypic analysis of Hodgkin's lymphomas in cytologic specimens. Diagn Cytopathol 1999; 20:278-284.

  50. Meda BA, Buss DH, Woodruff RD et al. Diagnosis and sub-classification of primary and recurrent lymphoma. Am J Clin Pathol 2000;113:6880699.

  51. Halliday BE, Slagel DD, Elseikh T et al. Diagnostic utility of MIC-2 immunocytochemical staining in the differential diagnosis of small blue cell tumors. Diagn Cytopathol 1998; 14:410-416.

  52. Perry A, Parisi JE, Kurtin PJ. Metastatic adenocarcinoma to the brain: an immunohistochemical approach. Human Pathol1997; 28:938-943.

  53. Blumenfeld W, Turi GK, Harrison G et al. Utility of cytokeratin 7 and 20 subset analysis as an aid in the identification of primary site of origin of malignancy in cytologic specimens. Diagn Cytopathol 1999; 20:63-66.

  54. Masood S. Estrogen and progesterone receptors in cytology: A comprehensive review. Diagn Cytopathol 1992; 8:475-491.

  55. Koyatsu J, Ishi K, Suzuki F et al. Usefulness of estrogen receptor detection using archival Papanicolaou-stained smears. Acta Cytol 1999;43:825-830.

  56. Vielh P, Magdelenat H, Mosseri V, et al. Immunocytochemical determination of estrogen and progesterone receptors on 50 fine-needle samples of breast cancer. Am J Clin Pathol 1992; 97: 254-261.

  57. Skoog L, Hummla S, Isaksson S, Tani E. Immunocytochemical analysis of receptors for estrogen and progesterone in fine-needle aspirates from breast carcinomas. Diagn Cytopathol 1990; 6:95-98.

  58. Marchetti E, Bagni A, Querzoli P, et al. Immunocytochemical detection of estrogen receptors by staining with monoclonal antibodies on cytologic specimens of human breast cancer. Acta Cytol 1988; 32:829-834.

  59. Weintraub J, Weintraub D, Redard M, Vassilakos P. Evaluation of estrogen receptors by immunocytochemistry on fine-needle aspiration biopsy specimens from breast tumors. Cancer 1987; 60:1163-1172.

  60. Ozello L, DeRosa C, Habif DV, Greene GL. An immunohistochemical evaluation of progesterone receptor in frozen sections, paraffin sections, and cytologic imprints of breast carcinomas. Cancer 1991; 67:455-462.

  61. Redard M, Vassilakos P, Weintraub J. A simple method for estrogen receptor antigen preservation in cytologic specimens containing breast carcinoma cells. Diagn Cytopathol 1989; 5:188-193.

  62. Suthipintawong C, Leong AS-Y, Chan K-W et al. Immunostaining of estrogen receptor, progesterone receptor, MIB 1 antigen, and c-erb-B-2 oncoprotein in cytologic specimens. Diagn Cytopathol 1997; 17:127-133.

  63. Briffod M, Hacene K, Le Doussal V. Immunohistochemistry on cell blocks from fine-needle cytopunctures of primary breast carcinomas and lymph node metastases. Mod Pathol 2000;13:841-50.

  64. Sandhu C, Slingerland J. Deregulation of the cell cycle in cancer. Cancer Detect Prev 2000;24:107-18

  65. Ross JS. DNA Ploidy and Cell Cycle Analysis in Pathology. New York: Igaku-Shoin Medical Publishers, Inc. 1996: pp 10-20.

  66. Ploton D, Visseaux-Coletto B, Canellas J C, et al. Semiautomatic quantification of silver-stained nucleolar organizer regions in tissue sections and cellular smears. Annal Quant Cytol Histol 1992, 14:14-23.

  67. Barsotti P, Ascoli V, Nardi F et al. Silver staining of interphase nucleolar organizer regions in cytologic smears previously stained by the Papanicolaou and May-Grunwald-giemsa techniques. Diagn Cytopathol 1990, 6:289-296.

  68. Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31:13-20.

  69. Rose DSC, Maddox PA, Brown DC. Which proliferation markers for routine immunohistology? Comparison of 5 antibodies. Am J Clin Pathol 1994; 47:1010-1014.

  70. Masood S. Prognostic factors in breast cancer: Use of cytologic preparations. Diagn Cytopathol 1995; 13:388-395.

  71. Leong S S-Y, Vinyuvat S, Suthipintawong C, et al. Comparative study of cell proliferation markers in breast carcinomas. Am J Clin Pathol 1995; 48:M83-87.

  72. Saleh H, Bober P, Tabaczka P. Value ofKi67 immunostain in identificationofmalignancy in serous effusions. Diagn Cytopathol 1999; 20:24-28.

  73. Colecchia M, Frigo B, Zucchi A, Leopardi O. p53 protein expression in fine-needle aspirates of breast cancer: An immunocytochemical assay for identifying high-grade ductal carcinomas. Diagn Cytopathol 1995; 13:128-133.

  74. Leong A S-Y, Robbins P, Spagnolo DV. Tumor genes and their proteins in cytologic and surgical specimens: Relevance and detection systems. Diagn Cytopathol 1995; 13:411-422.

  75. Ambros RA, Ross JS, Kallakury BVS, et al. p53 gene status in endometrial carcinomas showing diffuse positivity for p53 protein by immunohistochemical analysis. Modern Pathol 1995; 8:441-445.

  76. Saleh HA, Bober P, Tabaczka P. Improved detection of adenocarcinoma of serous fluidswith p53 immunocytochemistry. Acta Cytol 1998; 43:1330-1335.

  77. Corkill ME, Katz R. Immunocytochemical staining of regular cerbB-2 oncogene in fine-needle aspirates of breast carcinoma: A comparison with tissue sections and other breast cancer prognostic factors. Diagn Cytopathol 1994; 11:250-254.

  78. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54:2771-2777.

  79. Solomides CC, Zimmerman R, Bibbo M. Semiquantitative assessment of c-erb-B2 (HER-2)in cytologic specimens and tissue sections from breast carcinoma.Anal Quant Cytol Histol 1999;21:121-125.

  80. Kondo H, Sugano K, Fukayama N, et al. Detection of point mutations in the k-ras oncogene at codon 12 in pure pancreatic juice for the diagnosis of pancreatic carcinoma. Cancer 1994; 73:1589-1594.

  81. Apple SK, Novak JM, Hecht JR, et al. Sensitive and specific diagnosis of pancreatic and colangio-adenocarcinoma by polymerase chain reaction-based K-ras mutation detection in routine cytology smears. Am J Clin Pathol 1995; 104:326.

  82. Saurin J-C. Ki-Ras mutations help distinguish benign from malignant biliary strictures. Gut 2000; 47:357-361.

  83. Wick MR. Immunohistologic detection of ras oncogene products. Specific or spurious? Arch Pathol Lab Med 1989; 113:13-15.

  84. Ross JS, Cheung C, Sheehan C et al. E-cadherin cell adhesion molecule exprssion as a diagnostic adjunct in urothelial cytology. Diagn Cytopathol 1996; 14:310-15.

  85. Ross JS, del Rosario AD, Sanderson B, Bui HX. Selective expression of CD44 cell-adhesion molecule in thyroid papillary carcinoma fine-needle aspirates. Diagn Cytopahol 1996; 14:287-291.

  86. Chhieng D, Ross JS, McKenna BJ. CD44 immunostaining of thyroid fine-needle aspirates differentiates papillary carcinoma from other lesions with nuclear grooves and inclusions. Cancer (Cancer Cytopathol) 1997; 81:157-162.

  87. Saleh H, Masood S. Value of ancillary studies in fine-needle aspiration biopsy. Diagn Cytopathol 1995; 13:310-315.

  88. Ordonez NG, MacKay B. Electron microscopy in tumor diagnosis. Hum Pathol 1998; 29:1403-1411.

  89. Tubat-Herrera EA, Knowles K. Cytology: screening or diagnostic tool? Hum Pathol 1998; 29:1356-1366.

  90. Todd WJ, Burgdorfer W. Rapid processing of biopsy specimens for electron microscopy. Am J Clin Path 1982; 77:95-99.

  91. Akhtar M, Bedrossian CWM, Ali MA et al. Fine-needle aspiration biopsy of pediatric neoplasms. Diagn Cytopathol 1992; 8:258-265.

  92. Bals TF. Scanning electron microscopy of body fluids. Diagn Cytopathol 1992; 8:266-271.

  93. Dinque POV, Chen HB, Patil J, et al. Image analysis versus flow cytometry for DNA Ploidy quantitation of solid tumors: A comparison of six methods of sample preparation. Mod Pathol 1993; 6:270-275.

  94. Hendricks JB, Wilkinson EJ, Pharis PG, et al. Quantitative morphologic assessment of nuclei extracted from paraffin for DNA flow cytometry. Mod Pathol 1993; 6:565-569.

  95. Bauer TW, Tubbs RR, Edinger MG, et al. A prospective comparison of DNA quantitation by image analysis and flow cytometry. Am J Clin Pathol 1990; 93:322-326.

  96. Alanen KA, Lintu M, Joensuu H. Image cytometry of breast carcinomas that are diploid by flow cytometry. Anal Quant Cyto Histol 1998; 20:177-187.

  97. Hering B, Horn LC, Nenning H, Kuhndel K. Predictive value of DNA cytometry in CIN 1 and 2. Image analysis of 193 cases. Anal Quant Cytol Histol 2000;22(4):333-7.

  98. Wheeless LL, Pattern SF, Berkan TK, et al. Multi-dimensional slit-scan prescreening system: Preliminary results of a single band clinical study. Cytometry 1984; 5:1-8.

  99. Davey DD, Gallion H, Jenning CD. DNA cytometry in post-irradiation cervical-vaginal smears. Hum Pathol 1992; 23:1027-1031.

  100. Ballouk F, Ambros RA, Malfetano JH, et al. Evaluation of prognostic indicators in squamous carcinoma of the vulva including nuclear DNA content. Mod Pathol 1993; 6:371-375.

  101. Weyn B, Tjalma W, Van De Wouver G et al. Validation of nuclear texture, density, morphometry and tissue syntactic structure analysis as prognosticators of cervical carcinoma. Anal Quant Cytol Histol 2000; 22:373-382.

  102. Gourlay W, Chan V, Gilks CB. Screening for urothelial malignancies by cytologic analysis and flow cytometry in a community urologic practice: A prospective study. Mod Pathol 1995; 8:394-397.

  103. Koss LG, Sherman AB, Eppich E. Image analysis and DNA content of urothelial cells infected with human polyomavirus. Annal Quant Cytol Histol 1994; 6:89-94.

  104. Bakhos R, Shankey TV, Flanigan RC, Fisher S, Wojcik EM. Comparative analysis of DNA flow cytometry and cytology of bladder washings: review of discordant cases. Diagn Cytopathol 2000;22:65-9.

  105. Cajulis RS, Haines GK, Frias-Hidvegi D, McVary K, Bacus JW. Cytology, flow cytometry, image analysis and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: A comparative study. Diagn Cytopathol 1995; 13:214-224.

  106. Minimo C, Bagley D, McCue PA, Bibbo M. The role of DNA analysis in diagnosing upper urinary tract urothelial lesions. J Surg Pathol 1995;1:173-178.

  107. Schneller J, Eppich E, Greenebaum E, et al. Flow cytometry and Feulgen cytophotometry in evaluation of effusions. Cancer 1987; 59:1307-1313.

  108. Evans DA, Thornthwaite JT, Ng ABP, et al. DNA flow cytometry of pleural effusions: Comparison with pathology for the diagnosis of malignancy. Annal Quant Cytol Histol 1983; 5:19-27.

  109. Cibas ES. Applications of flow cytometric DNA analysis to diagnostic cytology. Diagn Cytopathol 1995; 13:166-171.

  110. Kayser K, Blum S, Beyer M, Haroske G, Kunze KD, Meyer W. Routine DNA cytometry of benign and malignant pleural effusions by means of the remote quantitation server Euroquant: a prospective study. J Clin Pathol 2000;53(10):760-4.

  111. Saha I, Dey P, Vhora H, Nijhawan R. Role of DNA flow cytometry and image cytometry on effusion fluid. Diagn Cytopathol 2000;22:81-5.

  112. Banks ER, Jennings CD, Jacobs S, et al. Comparative assessment of DNA analysis in effusions by image analysis and flow cytometry. Diagn Cytopathol 1994; 10:62-67.

  113. Joseph MG, Banerjee D, Harris P, Gibson S, McFadden RG. Multi-parameter flow cytometric DNA analysis of effusions: A prospective study of 36 cases compared with routine cytology and immunohistochemistry. Mod Pathol 1995; 8:686-693.

  114. Motherby H, Marcy T, Hecker M et al. Static DNA cytometry as a diagnostic aid in effusion cytology I. Anal Quant Cytol Histol 1998; 20:153-161.

  115. Thunissen FBJM, Buchholz RTF, Woutersen DP etal.Clinical value of DNA image cytometry in effusions with atypia. Diagn Cytopathol 1999; 21:112-116.

  116. Motherby H, Nadjari B, Remmerbach T et al. Static DNA cytometry as a diagnostic aid in effusion cytology II. Anal Quant Cytol Histol 1998; 20:162-168.

  117. Chen L-M, Lazcano O, Katzmann JA et al. The role of conventional cytology, immunocytochemistry and flow cytometric DNA ploidy in the evaluation of body cavity fluids. Am J Clin Pathol 1998; 109:712-721.

  118. Lazcano O, Chen LM, Tsai C, Li CY, Katzmann JA, Sebo TJ, Kimlinger TK, Baker J. Image analysis and flow cytometric DNA studies of benign and malignant body cavity fluids: reappraisal of the role of current methods in the differential diagnosis of reactive versus malignant conditions. Mod Pathol 2000;13:788-96

  119. Cibas ES, Malkin MG, Posner JB, et al. Detection of DNA abnormalities by flow cytometry in cells from cerebrospinal fluid. Am J Clin Pathol 1987; 38:570-577.

  120. Khan M, Bui H, Abdulla M, et al. Role of DNA content in determination by image analysis in confirmation of dysplasia in Barrett's Esophagus. Mod Pathol 1994; 7:169-174.

  121. McKenna BJ, Chhieng DC, Ilves R, et al. DNA ploidy determination by image analysis of monolayer smears prepared from mucosal brushing specimens. Mod Pathol 1996; (abstract) 9(1): 36A.

  122. Wolman SR. Fluorescence in situ hybridization: A new tool for the pathologist. Human Pathol 1994; 25:586-590.

  123. Waters JJ, Barlow AL, Gould CP. FISH. J Clin Pathol Mol Pathol 1998; 51:62-70.

  124. Abati A, Sanford JS, Fetsch P, Marincola FM, Wolman SR. Fluorescence in situ hybridization (FISH): A user's guide to optimal preparation of cytologic specimens. Diagn Cytopathol 1995; 13:486-492.

  125. Bergeron C, Ferenzcy A. In situ hybridization. In Bibbo M, Comprehensive Cytopathology, Philadelphia: W B Saunders & Co, 1991: pp 1052-1062.

  126. Autillo-Touati A, Joannes M, d'Ercole C et al. HPV typing by in situ hybridization on cervical cytologic smears with ASCUS. Acta Cytol 1998; 42:631-638.

  127. Sauer T, Beraki K, Jebsen PW et al. Ploidy analysis by in situ hybridization of interphase cell nuclei in fine-needle aspirates from breast carcinomas: correlation with cytologic grading. Diagn Cytopathol 1997; 17:267-271.

  128. Fiegl M, Kaufmann H, Zojer N et al. Malignant cell detection by fluorescence in situ hybridization (FISH) in effusions from patients with carcinoma. Hum Patholo 2000; 31:448-455.

  129. Bubendorf L, Grilli B, Sauter G, Mihatsch MJ, Gasser TC, Dalquen P. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001;116:79-86.

  130. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, King W. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000 Aug;2(3):116-23.

  131. Caraway NP, Du Y, Zhang HZ, Hayes K, Glassman AB, Katz RL. Numeric chromosomal abnormalities in small lymphocytic and transformed large cell lymphomas detected by fluorescence in situ hybridization of fine-needle aspiration biopsies. Cancer 2000;90:126-32.

  132. Lee W, Han K, Harris CP, et al. Use of FISH to detect chromosomal translocations and deletions. Am J Pathol 1993; 143:15-19.

  133. Wolman SR, Sanford JS, Flom K, Feiner H, Abati A, Bedrossian C. Genetic probes in cytology: Principals and applications. Diagn Cytopathol 1995; 13:429-435.

  134. Cox MC, Maffei L, Buffolino S et al. A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias. Am J Clin Pathol 1998; 109:24-31.

  135. Shipley J, Crew J, Birdsall S et al. Interphase fluorescence in situ hybridization and reverse transcription polmerase chain reaction as a diagnostic aid for synovial sarcoma. Am J Pathol 1996; 148:559-567.

  136. Rao UNM, Surti U, Hoffner L et al. Extraskeletal and skeletal myxoid chondrosarcoma: a multiparameter analysis of three cases including cytogenetic analysis and fluorescence in situ hybridization. Molec Diagn 1996; 1:99-107.

  137. Lee W, Han K, Haris CP et al. Uses of FISH to detect chromosomal translocations and deletions. Am J Pathol 1993; 143:15-19.

  138. Aktar M, Iqbal MA, Mourad W.Fine-needle aspiration biopsy diagnosis of small round cell tumorsof childhood: a comprehensiveaproach. Diagn Cytopahol 1999; 21:81-91.

  139. Arndt CAS, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999;341:340-353.

  140. Graadt van Roggen JF, Bovee JVMG, Hogendorn PCW. Diagnostic and prognostic implications of the unfolding molecular biology of bone and soft tissue tumors. J Cln Pathol 1999;52:481-489.

  141. Akerman M. New diagnostic techniques applied to fine needle aspirates. Acta Cytol 1998; 42:1315-1316.

  142. Ross JS, Fletcher JA. The HER-2/neu gene in breast cancer: prognostic factor predictive factor and target of therapy. Oncologist 1998; 3:237-252.

  143. Athanassidou PP, Veneti SZ, Kyrkou KA et al. Detection of c-Ha-ras oncogene expression in pleural and peritoneal smear effusions by in situ hybridzation. Cancer Detect Prevent 1993; 17:585-590.

  144. Eisenstein BL. The polymerase chain reaction. A new method for using molecular genetics for medical diagnosis. N Engl J Med 1990; 322:178-182.

  145. Hilborne LH, Grody WW. Diagnostic applications of recombinant nucleic acid technology: Basic technques: Laboratory Med 1991; 22:849-56.

  146. Grody WW, Hilborne LH. Diagnostic applications of recombinant nucleic acid technology: Neoplastic diseases. Laboratory Med 1992; 23:19-23.

  147. Hilborne LH, Grody WW. Diagnostic applications of recombinant nucleic acid technology: Infectious diseases. Laboratory Med 1992; 23:89-94.

  148. Grody WW, Hilborne LH. Diagnostic applications of recombinant nucleic acid technology: Genetic diseases. Laboratory Med 1992; 23:166-171.

  149. Bedford K, Jankowski JA. Clinical gene analysis and manipulation: Overview and applications in pathology. J Clin Pathol: Mol Pathol 1995; 48:M6-M11.

  150. Gray JW, Pinkel D. Molecular cytogenetics in human cancer diagnosis. Cancer 1992; 69:1536-1542.

  151. Greiner TG. Polymerase chain reaction: uses and potential applications in cytology. Diagn Cytopathol 1992; 8:61-64.

  152. Dejmek A, Yahata N, Ohyashiki K, Ebihara Y, Kakihana M, Hirano T, Kawate N, Kato H. In situ telomerase activity in pleural effusions: a promising marker for malignancy. Diagn Cytopathol 2001;24:11-5.

  153. Seki K, Suda T, Aoyagi Y, Sugawara S, Natsui M, Motoyama H, Shirai Y, Sekine T, Kawai H, Mita Y, Waguri N, Kuroiwa T, Igarashi M, Asakura H. Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification. Clin Cancer Res 2001;7:1976-81.

  154. Gelmini S, Crisci A, Salvadori B et al. Comparison of telomerase activity in bladder carcinoma and exfoliated cells collected in urine and bladderwashings, using a quantitative assay. Clin Cancer Res 2000; 6:2771-2776.

  155. Dejmek A, Yahata N, Ohyashiki K et al. Correlation between morphology and telomerase activity in cells from exfoliative lung cytologic specimens. Cancer (Cancer Cytopathol) 2000; 90:117-125.

  156. Bialkowska-Hobrzanska H, Bowles L, Bukala B, Joseph MG, Fletcher R, Razvi H. Comparison of human telomerase reverse transcriptase messenger RNA and telomerase activity as urine markers for diagnosis of bladder carcinoma. Mol Diagn 2000;5:267-77.

  157. Rogers BB. Nucleic acid amplification and infectious disease. Hum Pathol 1993; 25:591-593.

  158. Komminoth P, Long AA, Ray R, Wolfe HJ. In situ polymerase chain reaction detection of viral DNA, single-copy genes and gene rearrangements in cell suspensions and cytospins. Diagn Mol Pathol 1992; 1:85-87.

  159. Read SJ, Burnett D, Fink CG. Molecular techniques for clinical diagnostic virology. J Clin Pahol 2000; 53:502-506.

  160. Okuyama T, Takahashi R, Mori M et al. Polymerase chain reaction amplification of trichomonas vaginalis DNA from Papanicoloaou-stainedsmears. Diagn Cytopathol 1998; 19:437-440.

  161. Keating JT, Ince T, Crum CP. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol 2001;8:83-92.

  162. Birner P, Bachtiary B, Dreier B, Schindl M, Joura EA, Breitenecker G, Oberhuber G. Signal-amplified colorimetric in situ hybridization for assessment of human papillomavirus infection in cervical lesions. Mod Pathol 2001 Jul;14(7):702-9.

  163. Stoler MH. Advances in cervical screening technology. Mod Pathol 2000;13:275-84.

  164. Patterson B, Domanik R, Wernke P, Gombrich M. Molecular biomarker-based screening for early detection of cervical cancer. Acta Cytol 2001;45:36-47.

  165. Han M, Schoenberg MP. The use of molecular diagnostics in bladder cancer. Urol Oncol 2000; 5:87-92.

  166. Ross JS, Cohen MB. Biomarkers for the detection of bladder cancer. Adv Anat Pathol 2001;8:37-45.

  167. Poljak M, Barlic J, Seme K, et al. Isolation of DNA from archival Papanicalaou stained cytological smears using a simple salting-out procedure. J Clin Pathol Mol 1995; 48:M55-M56.

  168. Katz RL, Hirsch-Ginsburg C, Childs C et al. The role of gene rearrangements for antigen receptors in the diagnosis of lymphoma obtained by fine-needle aspiration. Am J Clin Pathol 1991; 96:479-490.

  169. Lubiski J, Chosia M, Huebner K. Molecular genetic analysis in the diagnosis of lymphoma in fine needle aspiration I. Anal Quant Cytol Histol 1988; 10: 391-398.

  170. Lubiski J, Chosia M, Huebner K. Molecular genetic analysis in the diagnosis of lymphoma in fine needle aspiration II. Anal Quant Cytol Histol 1988; 10: 399-404.

  171. Torlakovic E, Berner A, Risberg B. Detection of immunoglobulin heavy chain rearrangements by polymerase chain reaction analysis on lymph node imprints and fine needle aspiration smears. Diagn Cytopathol 1999;20:333-338.

  172. Kondo H, Sugano K, Fukayama N et al. Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for the diagnosis of pancreatic carcinoma. Cancer 1994; 73:1589-2594.

  173. Tockman MS. Advances in sputum analysis for screening and early detection of lung cancer. Cancer Control 2000; 7:19-24.

  174. Yamashita K, Kuba T, Shinoda H et al.Detectio of K-ras point mutations in the supernatants of peritoneal and pleural effusions for diagnosis complementary to cytologic examination. Am J Clin Pathol 1998; 19:704-711.

  175. Cunigham VJ, Markham N, Shroyer AL et al. Detection of telomerase expression in fine-needle aspirates and fluids. Diagn Cytopathol 1998; 18:431-436.

  176. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science 1997; 278:1054-1059.

  177. Nilsson G, Wang M, Wejde J et al. Reverse transcriptase polymerase chain reaction on fine needle asprates for rapid detection of translocations in synovial sarcoma. Acta Cytol 1998; 42:1317-1324.